Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins, Synthego Sign Distribution Agreement for Synthetic Single-Guide RNA Products

NEW YORK (GenomeWeb) – Genome engineering firm Synthego announced today that it has signed a deal with Eurofins Genomics to distribute Synthego's synthetic single guide RNA (sgRNA) products to its customers in 44 countries.

Financial terms of the deal were not disclosed.

Silicon Valley, California-based Synthego said its synthetic, chemically modified, and unmodified sgRNAs deliver editing efficiencies of up to 97 percent for researchers engaged in CRISPR gene editing experiments, which allows for editing in virtually any cell type. Synthetic guide RNA products that will be available under the Eurofins Scientific brand include synthetic crRNA:tracrRNA, synthetic sgRNAs, and chemically modified synthetic sgRNA.

Eurofins Genomics is part of the food, pharmaceutical, and environmental laboratory testing company Eurofins Scientific Group, and specializes in life science technologies for academic institutions, biotech companies, and the pharma industry.

"CRISPR and genome engineering has the potential to address some of society's biggest challenges, but more scientists need access to products that can accelerate their research," Synthego Chief Operating Officer Ted Tisch said in a statement. "The cooperation with Eurofins Genomics offers an expert network and a reliable and wide distribution organization. Synthego's synthetic RNA products have proven to be predictable, scalable, and efficient in helping customer capture this potential."

In October 2017, Synthego signed an agreement with Thermo Fisher Scientific to market and sell its synthetic guide RNA products under a Thermo Fisher brand. Synthego planned to manufacture synthetic guide RNAs for Thermo Fisher, including a synthetic crRNA:tracrRNA, a synthetic single guide RNA, and a chemically modified sgRNA to be sold under Thermo Fisher's Invitrogen TrueGuide brand.

And this past October, Synthego said it had raised $110 million in a Series C financing round, which it planned to use to continue marketing its Engineered Cells and CRISPRevolution product lines, further expand into Europe and Asia, and continue extending its full stack genome engineering platform.